|Titre :||Cardiovascular toxicity of novel psychoactive drugs: Lessons from the past (2012)|
|Auteurs :||P. DAWSON ; J. D. MOFFATT|
|Type de document :||Article : Périodique|
|Dans :||Progress in Neuro-Psychopharmacology and Biological Psychiatry (Vol.39, n°2, 3 December 2012)|
|Article en page(s) :||244-252|
|Discipline :||PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)|
Thésaurus TOXIBASEDROGUES DE SYNTHESE ; APPAREIL CARDIOVASCULAIRE ; MORBIDITE ; MORTALITE ; PHARMACOLOGIE ; SEROTONINE ; EVOLUTION ; ECSTASY ; MEPHEDRONE ; DOPAMINE ; VASOCONSTRICTION ; CATECHOLAMINES ; BRONCHODILATATEURS ; AMPHETAMINES
The long use of ephedrine, amphetamines, cocaine, LSD and more recently 3,4-methylenedioxy-N-methylamphetamine (MDMA; “Ecstasy”) allows us to predict with some confidence what cardiovascular risks are likely to be associated with novel psychoactive substances (NPS). Once the probably multiple biological activities of a compound are known it is possible to define the likely risks of cardiovascular toxicity. Agonists of 5-HT2A receptors or alpha-adrenoceptors may cause vasoconstriction and tissue ischemia. Drugs which have agonist affinity for 5-HT2B receptors will probably promote heart valve fibrosis leading to heart failure. Compounds that interfere with uptake of dopamine or 5-hydroxytryptamine (5-HT) are likely to also have effects on noradrenergic neurotransmission and lead to sympathomimetic effects on the heart and vasculature. Drugs that cause dopamine release, or inhibit uptake are likely to be addictive and lead to chronic use. Other drugs (particularly the so-called empathogens) are associated with weekly usage in social settings; over time such use can lead to cardiovascular harm. Defining which of these effects NPS have is an important element of predicting the harm they may cause and informing those appointed to introduce regulations to control them.
• We review the recent history of psychoactive drug abuse.
• We describe the associations between drugs of abuse and cardiovascular toxicity.
• We highlight potential risks associated with novel psychoactive substances.
|Domaine :||Drogues illicites / Illicit drugs|
|Sous-type de document :||Revue de la littérature / Literature review|
|Affiliation :||Division of Biomedical Sciences, St. George's, University of London, London, UK|